2023 World Conference on Lung Cancer (Posters)-EP12.01. Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment

EP12.01. Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment - PDF(Abstract)

Back to course

Pdf Summary

This case report discusses the treatment of a female lung cancer patient with brain metastasis and a large lung lesion using a combination of aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor, and radiotherapy. The patient had a stage IVB adenocarcinoma with EGFR exon 19 deletion mutation and experienced dyspnea and intracranial hypertension. To manage the disease, the patient received aumolertinib and upfront cranial radiotherapy simultaneously. This led to a significant reduction in symptoms of intracranial hypertension and complete remission of intracranial metastatic lesions.<br /><br />A follow-up CT examination showed complete remission of mediastinal and axillary lymph nodes, but stable disease in the primary lung tumor. To further enhance local control, the patient received salvage chest radiotherapy along with aumolertinib, resulting in a noticeable shrinkage of the primary tumor. The patient continued to receive aumolertinib as maintenance treatment, and so far, the primary tumor and intracranial metastatic lesions have remained in complete remission for over 36 months.<br /><br />The treatment regimen of aumolertinib combined with upfront cranial and thoracic radiotherapy has shown significant antitumor activity and excellent safety in this case. The patient only experienced a mild grade 1 radiation-induced pneumonia, and no other adverse events were observed. The authors conclude that aumolertinib combined with synchronous upfront cranial and thoracic radiotherapy is effective and safe, suggesting that this treatment approach can be considered in similar cases.<br /><br />This study highlights the potential benefits of combining targeted therapy with radiotherapy for patients with metastatic non-small cell lung cancer harboring EGFR mutations. The use of aumolertinib in combination with upfront radiotherapy may offer improved disease control and survival outcomes. However, more research and clinical trials are needed to validate these findings and determine the optimal treatment strategies for this patient population.

Asset Subtitle

Qiang Wu

Meta Tag

Speaker Qiang Wu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung cancer

brain metastasis

lung lesion

aumolertinib

EGFR-tyrosine kinase inhibitor

radiotherapy

adenocarcinoma

EGFR exon 19 deletion mutation

intracranial hypertension

complete remission